[Translated article] Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement - A Multicenter Cross-Sectional CLINI-AEDV Study.

Dermatology Dermatología Epidemiology Epidemiología Escabiosis Resistance Resistencia Scabies Terapéutica Therapeutics

Journal

Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062

Informations de publication

Date de publication:
03 Nov 2023
Historique:
received: 28 06 2023
accepted: 28 08 2023
pubmed: 6 11 2023
medline: 6 11 2023
entrez: 3 11 2023
Statut: aheadofprint

Résumé

Several studies support the hypothesis that scabies is on the rise in Spain. There are also concerns about the possible development of resistance to treatment and an increase in atypical presentations. The aims of this study were to describe the demographic and clinical characteristics of patients with scabies seen by dermatologists in Spain, to identify the possible emergence of atypical forms of scabies, and to explore the frequency of treatment failures and associated risk factors. We conducted an observational, cross-sectional, multicenter study of data collected prospectively in April and May 2023 using the CLINI-AEDVp platform created by the Spanish Academy of Dermatology and Venereology (AEDV). Participating dermatologists from 31 hospitals in 15 of Spain's autonomous communities recorded 186 cases of active scabies (51% in women) during the study period. A diagnostic certainty level of A, B or C as per the International Alliance for the Control of Scabies Consensus Criteria was required for diagnosis. Overall, 92% of patients had clinical features of classic scabies and 66% had already been treated with a scabicide for the current episode. Of the treated patients, only 36% had received and completed adequate treatment (including the simultaneous treatment of all household members) and 50% had not received clear written recommendations. In a high proportion of scabies cases, the patient has already received treatment. In those cases, we observe several remediable shortcomings that could explain why some of these treatments fail. Remedying these deficiencies should lead to better control of scabies and an improved assessment of the actual effectiveness of currently available scabicides.

Sections du résumé

BACKGROUND BACKGROUND
Several studies support the hypothesis that scabies is on the rise in Spain. There are also concerns about the possible development of resistance to treatment and an increase in atypical presentations. The aims of this study were to describe the demographic and clinical characteristics of patients with scabies seen by dermatologists in Spain, to identify the possible emergence of atypical forms of scabies, and to explore the frequency of treatment failures and associated risk factors.
METHODS METHODS
We conducted an observational, cross-sectional, multicenter study of data collected prospectively in April and May 2023 using the CLINI-AEDVp platform created by the Spanish Academy of Dermatology and Venereology (AEDV).
RESULTS RESULTS
Participating dermatologists from 31 hospitals in 15 of Spain's autonomous communities recorded 186 cases of active scabies (51% in women) during the study period. A diagnostic certainty level of A, B or C as per the International Alliance for the Control of Scabies Consensus Criteria was required for diagnosis. Overall, 92% of patients had clinical features of classic scabies and 66% had already been treated with a scabicide for the current episode. Of the treated patients, only 36% had received and completed adequate treatment (including the simultaneous treatment of all household members) and 50% had not received clear written recommendations.
CONCLUSIONS CONCLUSIONS
In a high proportion of scabies cases, the patient has already received treatment. In those cases, we observe several remediable shortcomings that could explain why some of these treatments fail. Remedying these deficiencies should lead to better control of scabies and an improved assessment of the actual effectiveness of currently available scabicides.

Identifiants

pubmed: 37923079
pii: S0001-7310(23)00871-2
doi: 10.1016/j.ad.2023.10.037
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

C Galván Casas (C)

Unidad de Investigación STI & NTD, Fundación Lucha contra las Infecciones, Badalona, Barcelona, España; Servicio de Dermatología, Hospital Universitario de Móstoles, Móstoles, Madrid, España.

R Ruiz-Villaverde (R)

Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, España.

Á Prados-Carmona (Á)

Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, España.

Á Fernández Camporro (Á)

Servicio de Dermatología, Hospital Universitario de Cabueñes, Gijón, Asturias, España.

A G Angulo Menéndez (AG)

Clínica Serveis Mèdics Penedés, Vilanova i la Geltrú, Barcelona, España.

M C Álvarez-Buylla Puente (MC)

Servicio de Dermatología, Hospital Universitario Son Llàtzer, Palma, Palma de Mallorca, España.

P Pasquali (P)

Centro Médico Pasquali & Asociados, Cambrils, Tarragona, España.

Á Aguado Vázquez (Á)

Servicio de Dermatología, Hospital Universitario Doctor Peset, Valencia, España.

E Masferrer (E)

Clínica Derma-Balmes, Barcelona, España.

L Rodríguez González (L)

Clínica Dermatológica Gijonesa, Gijón, Asturias, España.

D Ruiz-Sánchez (D)

Servicio de Dermatología, Hospital Universitario de Cabueñes, Gijón, Asturias, España.

C F Caballero-Linares (CF)

Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España.

A Tejera-Vaquerizo (A)

Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, España.

N Iglesias-Pena (N)

Servicio de Dermatología, Hospital San Rafael, A Coruña, España.

S Fernández de Piérola (S)

Clínica Fernández de Piérola, Logroño, La Rioja, España.

C Maldonado-Seral (C)

Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.

M Armengot-Carbó (M)

Servicio de Dermatología, Hospital General Universitario de Castellón, Castellón, España.

L Alonso-Naranjo (L)

Consultorio Dermatológico, Arrecife, Las Palmas, España.

R Barros Tornay (R)

Servicio de Dermatología, Hospital Universitario de Cabueñes, Gijón, Asturias, España.

T Solano Novo (T)

Clínica Solano, Vigo, Pontevedra, España.

V Fernández Tapia (V)

Servicio de Dermatología, Hospital Universitario Son Llàtzer, Palma, Palma de Mallorca, España.

A Martín-Gorgojo (A)

Servicio ITS/Dermatología, Sección Especialidades Médicas, Ayuntamiento de Madrid, Madrid, España.

J Adsuar Mas (J)

Servicio de Dermatología, Hospital Universitario Son Llàtzer, Palma, Palma de Mallorca, España.

M E Parera Amer (ME)

Servicio de Dermatología, Hospital Universitario Son Llàtzer, Palma, Palma de Mallorca, España.

P Pérez Feal (P)

Servicio de Dermatología, Hospital Universitario Lucus Augusti, Lugo, España.

R Taberner (R)

Servicio de Dermatología, Hospital Universitario Son Llàtzer, Palma, Palma de Mallorca, España.

M Utrera-Busquets (M)

Clínica de Dermatología Dra. Pilar Cordero, Huelva, España.

I Vicente Sánchez (I)

Organización sanitaria Integrada Barrualde-Galdakao, Vizcaya, España.

L Palacio Aller (L)

Servicio de Dermatología, Hospital Universitario de Cabueñes, Gijón, Asturias, España.

I Sánchez-Gutiérrez (I)

Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España.

T Usero-Bárcena (T)

Servicio de Dermatología, Hospital Universitario Lucus Augusti, Lugo, España.

B Aldea Manrique (B)

Servicio de Dermatología, Hospital Universitario Miguel Servet, Zaragoza, España.

A Sánchez Velázquez (A)

Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España.

E Martínez García (E)

Servicio de Dermatología, Hospital Universitario Virgen de la Victoria, Málaga, España.

M Grau-Pérez (M)

Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España; Unidad de Investigación, Academia Española de Dermatología y Venereología (AEDV), Madrid, España. Electronic address: merce.grau@equipo.aedv.es.

I García-Doval (I)

Unidad de Investigación, Academia Española de Dermatología y Venereología (AEDV), Madrid, España.

Classifications MeSH